All In Biotech

Drug Trial Radar · NCT06013969

A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares

Effisayil® REP: An Open-label, Multicenter, Single-arm, Post-marketing Trial (in Select Countries) to Evaluate Efficacy and Safety and the Impact of Immunogenicity on Efficacy, Safety, and Pharmacokinetics of Spesolimab i.v. in Treatment of Patients With Generalized Pustular Psoriasis (GPP) Presenting With a Recurrent Flare Following Their Initial GPP Flare Treatment With Spesolimab i.v.

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

42

Actual

Start

Oct 22, 2023

Primary completion

May 13, 2026

Study completion Sep 2, 2026

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
Collaborators
Boehringer Ingelheim
First posted
Aug 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with a serious skin disease called generalized pustular psoriasis (GPP) who have repeated flares of GPP. The purpose of this study is to find out whether a medicine called spesolimab helps people with repeated flares of GPP. Participants are given a single dose of spesolimab as an infusion into a vein on the first day of an outbreak of GPP. They may be given a second dose 1 week later if doctors think it is helpful. They are also treated for additional GPP flares. During the time of the study, doctors regularly examine participants' skin for signs of GPP to see how well the treatment works and take blood samples. The doctors also regularly check participants' health and take note of any unwanted effects.

Conditions

  • Generalized Pustular Psoriasis

Interventions

  • SpesolimabDrug

    Spesolimab intravenous (i.v.) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Achievement of a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation sub-score of 0 indicating no visible pustules at Week 1Time frame: Up to week 1

Locations

35 sites in 17 countries. Site status is shown where the registry gives one.

  • University of California Irvine

    Irvine, California

  • Red River Research Partners, LLC

    Fargo, North Dakota

  • Liverpool Hospital

    Liverpool, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • Hospital Universitario Evangelico Mackenzie

    Curitiba, Brazil

  • Faculdade de Medicina do ABC

    Santo André, Brazil

  • Southern Medical University Dermatology Hospital

    Guangzhou, China

  • Shanghai Skin Disease Hospital

    Shanghai, China

  • Shanghai Tenth People's Hospital

    Shanghai, China

  • HOP Trousseau

    Chambray-lès-Tours, France

  • HOP Saint-Louis

    Paris, France

  • Universitätsklinikum Frankfurt

    Frankfurt am Main, Germany

  • Klinikum der Universität München AÖR

    München, Germany

  • SP medical college and associated group of hospitals

    Bikaner, India

  • Nkp Salve Institute of Medical Sciences and Lata Mangeshkar Hospital

    Nagpur, India

  • ASST degli Spedali Civili di Brescia

    Brescia, Italy

  • Hospital Selayang

    Batu Caves, Malaysia

  • Hospital Pulau Pinang-Pulau Pinang-21953

    Georgetown Pulau Pinang, Malaysia

  • Hospital Sultanah Aminah

    Johor Bahru, Malaysia

  • Hospital Sultan Ismail

    Johor Bahru, Malaysia

  • Hospital Kuala Lumpur

    Kuala Lumpur, Malaysia

  • Hospital Putrajaya

    Putrajaya, Malaysia

  • Sunway Medical Centre

    Selangor Darul Ehsan, Malaysia

  • National University Hospital-Singapore-42005

    Singapore, Singapore

  • Nelson Mandela Academic Clinical Research Unit (NeMACRU)

    Mthatha, Eastern Cape, South Africa

  • Seoul National University Hospital

    Seoul, South Korea

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hospital Universitario Ramon Y Cajal

    Madrid, Spain

  • National Taiwan University Hospital

    Taipei, Taiwan

  • Chang Gung Memorial Hospital, Linkou

    Taoyuan, Taiwan

  • Srinagarind Hospital

    Khon Kaen, Thailand

  • Maharat Nakhonchiangmai Hospital

    Muang Chiang Mai, Thailand

  • Hedi Chaker Hospital, Department of Dermatology

    Sfax, Tunisia

  • Farhat Hached Hospital

    Sousse, Tunisia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.